Navigation Links
Labopharm Submits Complete Response to FDA as a Result of Outcome of Appeal Process for Once-Daily Tramadol
Date:7/2/2008

LAVAL, QC, July 2 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it has submitted a complete response to the Food and Drug Administration (FDA) per the suggestion of Dr. Douglas Throckmorton, M.D., the FDA's Deputy Director, Center for Drug Evaluation and Research (CDER), as the next step in the regulatory path towards potential U.S. approval of the Company's once-daily formulation of tramadol. The complete response centers on the additional analysis of existing data using the methodology put forward by Dr. John K. Jenkins, M.D., Director for the Office of New Drugs, CDER, in his letter earlier this year.

Upon acceptance for review of the response, the FDA will assign an action date under the Prescription Drug User Fee Act (PDUFA).

About Labopharm's Once-Daily Tramadol Product

Labopharm's once-daily tramadol product is based on the Company's proprietary Contramid(R) technology, which provides a dual matrix delivery system allowing both rapid and sustained drug release that maintains blood levels within the therapeutic range providing a full 24 hours of pain relief. The Company believes that maintaining drug concentrations within the therapeutic range has the advantage of fewer and less severe side effects while maintaining efficacy. Under its global commercialization program, Labopharm's once-daily tramadol product has been launched in 12 countries, including the five largest markets in Europe and Canada and is approved in 19 other countries. Including those countries in which its product has been launched, Labopharm has licensing and distribution agreements in place for more than 50 markets globally.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets
'/>"/>

SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Labopharm Receives Response from FDA Regarding its Once-Daily Tramadol Product
2. Labopharm Reports Results for First Quarter Fiscal 2008
3. Labopharm announces details for first quarter results conference call and annual meeting
4. Labopharm Appoints Dr. Claire Brulle as Senior Vice-President and Chief Medical Officer
5. Labopharm Appeals FDAs Decision on Once-Daily Tramadol to Next Supervisory Level After Additional Analysis Supports Efficacy
6. Labopharm Initiates Phase III Clinical Trial for Twice-Daily Formulation of Tramadol-Acetaminophen
7. Labopharms Once-Daily Tramadol Approved in South Korea and Australia
8. Labopharm to host conference call Thursday, February 21, 2008 at 8:30 a.m. (ET)
9. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... Los Angeles, California (PRWEB) , ... August 04, ... ... bearing drawer slides to Los Angeles commercial customers. Finding reliable hardware can ... create unfortunate liabilities. When putting an office together or designing a new ...
(Date:8/4/2015)... ... August 04, 2015 , ... Worldwide ... Power Products is expanding its reach in Texas. Effective July 1st of this ... North Texas generator division. With the North Texas acquisition, Worldwide Power Products ...
(Date:8/4/2015)... ... 2015 , ... Many men are confused about the safety of testosterone replacement ... as a voice of authority for men seeking accurate information about testosterone. , ... and expertise in the safe and effective treatment of low testosterone. In recent years, ...
(Date:8/4/2015)... ... August 04, 2015 , ... Increasingly, ... Google” before calling a physician. In an effort to share more and better ... provider in Pennsylvania to publicly share patient satisfaction ratings and comments about its ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... mesothelioma patients whose cancer has come back: Retreatment may be a viable option. ... to read it now. , According to surgeons at the University of ...
Breaking Medicine News(10 mins):Health News:Ryadon, Inc. is Now Offering their Ball Bearing Drawer Slides to Los Angeles, CA Commercial Customers 2Health News:Ryadon, Inc. is Now Offering their Ball Bearing Drawer Slides to Los Angeles, CA Commercial Customers 3Health News:Ryadon, Inc. is Now Offering their Ball Bearing Drawer Slides to Los Angeles, CA Commercial Customers 4Health News:North Texas Acquisition Press Release 2Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 2Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 3Health News:UPMC 1st in Pa. to Share Provider Ratings 2Health News:UPMC 1st in Pa. to Share Provider Ratings 3Health News:New Research Reveals Some Patients Experience Extended Mesothelioma Survival with Repeat Treatment, According to Surviving Mesothelioma 2
... MYL ),today announced that in accordance with its 2.139 ... dividend of $15.53,per share (based on the annual dividend rate ... the time period from the date of,issuance to February 15, ... of record as of February 1, 2008., Mylan Inc. ...
... 30 OxySure(R) Systems, Inc.,announced today that the ... World,s,Best Technologies (WBT) in 2008. OxySure(R) has developed ... two inert, proprietary,powders. The company,s inclusion into the ... Generator, Model 615, which OxySure(R) launched,in late 2007. ...
... safe dosages of the isotope astatine-211 for patients ... to find that not only was the isotopes ... damaging sensitive healthy brain cells, but the patients ... much as five times or more cell-killing efficiency ...
... Low in Seasonal Illness affects sales of Cough ... Matrixx Initiatives, Inc.,(Nasdaq: MTXX ), an over-the-counter ... consumers with "Better Ways to Get,Better(R)," today announced ... nine months ended December 31, 2007. Third quarter ...
... Shares at the Annual Meeting of ... Stockholders on March 11, 2008), BEDFORD, Mass., ... technologies company specializing in,diagnostics imaging systems and interventional devices dedicated to ... Directors,has approved a two-for-one stock split, to be effected in the ...
... preserving Blue Cross,s nonprofit mission gives Michigan ... LANSING, Mich., Jan. 30 Creation of ... people rejected by,commercial insurers and HMOs because of ... the Michigan Senate Health Policy Committee,today. The Senate ...
Cached Medicine News:Health News:OxySure(R) Systems, Inc. Named to 2008 World's Best Technologies (WBT) List For its Unique, Safe and Easy to Use Portable Emergency Oxygen Generator, Which Provides Medical Oxygen Without the Need for Compressed Tanks 2Health News:Treatment capitalizes on unique qualities of radioisotope to prolong lives of brain tumor patients 2Health News:Treatment capitalizes on unique qualities of radioisotope to prolong lives of brain tumor patients 3Health News:Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share 2Health News:Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share 3Health News:Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share 4Health News:Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share 5Health News:Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share 6Health News:Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share 7Health News:Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share 8Health News:Hologic Announces Two-For-One Stock Split 2Health News:Hologic Announces Two-For-One Stock Split 3Health News:Blue Cross Blue Shield of Michigan Says Guaranteed Access Provisions of Insurance Reform Bills Protect Michigan Consumers Twice-Over 2Health News:Blue Cross Blue Shield of Michigan Says Guaranteed Access Provisions of Insurance Reform Bills Protect Michigan Consumers Twice-Over 3
(Date:8/4/2015)... Transparency Market Research has published ... Market (BambniTest, Harmony, informaSeq, MaterniT21 PLUS, NIFTY, Panorama, PrenaTest, ... Volume, Share, Growth, Trends and Forecast 2014 - 2022 ... published by Transparency Market Research " Non-invasive Prenatal Testing ... Trends and Forecast 2014 - 2022 ", the global ...
(Date:8/4/2015)... Research and Markets ( http://www.researchandmarkets.com/research/nl392k/alcohol ) has announced the ... (Household & Personal Care, Pharmaceutical, Oilfield, Agrochemicals, and Others) ... report to their offering. The market ... in 2014 and is projected to grow at a ... data mentioned in the report is based on the ...
(Date:8/4/2015)... SAN DIEGO , Aug. 4, 2015  Mirati Therapeutics, ... focusing on genetic and epigenetic drivers of cancer, will be ... August 11, 2015 at 1:55 p.m. ET (10:55 a.m. PT) ... Baum , M.D., Ph.D., president and CEO of Mirati, will ... of the presentation will be accessible on the "Investors" page ...
Breaking Medicine Technology:Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 2Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 3Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 4Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 5Global Alcohol Ethoxylate Market 2015 - Market Trends, Forecasts to 2019 for the $5.1 Billion Industry 2Global Alcohol Ethoxylate Market 2015 - Market Trends, Forecasts to 2019 for the $5.1 Billion Industry 3Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference 2Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference 3
... YORK, Feb. 1, 2011 Reportlinker.com announces that a ... Pen Injectors ... of an increasing number of drugs in pre-filled disposable ... pens at the expense of other drug delivery methods ...
... Reportlinker.com announces that a new market research report ... Fludarabine - Comprehensive patent search ... with the industry benchmark in comprehensive patent information. ... professional patent search performed by our expert team, ...
Cached Medicine Technology:Reportlinker Adds Fludarabine - Comprehensive Patent Search 2Reportlinker Adds Fludarabine - Comprehensive Patent Search 3Reportlinker Adds Fludarabine - Comprehensive Patent Search 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: